Moguće interakcije s lijekovima

Ako koristite bilo koji od dolje navedenih lijekova/pripravaka, ne preporuča se da uzimate dodatne mineralne pripravke s jodom bez dozvole liječnika.

Amiodaron – Ovaj lijek koji se koristi u liječenju nepravilnog srčanog ritma sadrži jod. Uzimanje joda zajedno s amiodaronom može rezultirati pretjerano visokim razinama joda u krvi, što može utjecati na funkciju štitnjače.[1-6]

Antitireoidni lijekovi – Ovi se lijekovi koriste u liječenju hipertiroidizma, a uključuju metimazol i propiltiouracil. Uzimanje visokih doza joda i ovih lijekova može uzrokovati hipotiroidizam.[1,7-9]

Blokatori receptora angiotezina II – Ovi lijekovi, kao što su losartan, valsartan, irbesartan i kandesartan, telmisartan i eprosartan, mogu uzrokovati značajno povećanje razina kalija u krvi. Većina dodataka prehrani s jodom sadrži jod u obliku kalijeva jodida, što može rezultirati povećanim razinama kalija u krvi, pa je potreban oprez u slučaju uzimanja ovih lijekova.[10-12]

Diuretici koji štede kalij – Ovi lijekovi, kao što je amilorid, spironolakton i triamteren, smanjuju urinarno izlučivanje kalija, što može rezultirati nakupljanjem kalija u organizmu, tj. hiperkalemijom. Većina dodataka prehrani s jodom sadrži jod u obliku kalijeva jodida, to može rezultirati povećanim razinama kalija u krvi, pa je potreban oprez u slučaju uzimanja ovih lijekova.[13-18]

Inhibitori angiotenzin konvertirajućeg enzima (ACE inhibitori) – Ovi se lijekovi koriste u liječenju hipertenzije i kongestivnog zatajenja srca, a uključuju kaptopril, enalapril, ramipril, benazepril, lisinopril, moeksipril, kvinapril i dr. Istraživanja pokazuju da mogu povećavati razine kalija u krvi, tj. hiperkalemiju. Većina dodataka prehrani s jodom sadrži jod u obliku kalijeva jodida, to može rezultirati povećanim razinama kalija u krvi, pa je potreban oprez u slučaju uzimanja ovih lijekova.[19-23]

Litij – Istraživanja pokazuju da litij negativno utječe na funkciju štitnjače. Kombinacija kalijeva jodida i litija dodatno može štetiti. Naime, navedena kombinacija može uzrokovati hipotiroidizam, tj. litij može povećati učinak joda na štitnjaču.[1,24-28]

Varfarin – Varfarin, antikoagulans, može imati smanjeno djelovanje, ako se uzima uz kalijev jodid.[1,29]

Interakcije joda s hranjivim tvarima

Selen – Istraživanja pokazuju da nedostatak selena može dodatno pogoršati simptome nedostatka joda. Jod je potreban za sintezu hormona štitnjače, no potrebni su i selen-ovisni enzimi (jodotironin dejodinaze) za reakciju pretvorbe tiroksina (T4) u biološki aktivan trijodotironin (T3).[1,30,31]

Vitamin A – Istraživanja pokazuju da nedostatak vitamina A može dodatno pogoršati simptome nedostatka joda.[1,32,33]

Željezo – Istraživanja pokazuju da nedostatak željeza može dodatno pogoršati simptome nedostatka joda.[1,32,34]

"Literatura"

1. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine (2001) Dietary reference intakes for vitamin A, vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, National Academy Press, Washington.

2. Ahmed, S., Van Gelder, I.C., Wiesfeld, A.C. i sur. (2011) Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin. Endocrinol. (Oxf). 75, 388-394.

3. Mosher, M.C. (2011) Amiodarone-induced hypothyroidism and other adverse effects.Dimens. Crit. Care Nurs. 30, 87-93.

4. Hofmann, A., Nawara, C., Ofluoglu, S. i sur. (2008) Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. Wien Klin. Wochenschr. 120, 493-498.

5. Piga, M., Serra, A., Boi, F. i sur. (2008) Amiodarone-induced thyrotoxicosis. A review. Minerva Endocrinol. 33, 213-228.

6. Tsadok, M.A., Jackevicius, C.A., Rahme, E. i sur. (2011) Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations. Can. Med. Assoc. J. 183, E817-E823.

7. Choo, Y.K., Yoo, W.S., Kim, D.W., Chung, H.K. (2010) Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves’ disease. Thyroid. 20, 949-954.

8. Tamai, H., Hirota, Y., Kasagi, K. i sur. (1987) The Mechanism of Spontaneous Hypothyroidism in Patients with Graves’ Disease after Antithyroid Drug Treatment J. Clin. Endocrinol. Metab.64, 718-722.

9. Copper, D.S. (2005) Antithyroid Drugs. N. Engl. J. Med. 352, 905-917.

10. Perazella, M.A. (2000) Drug-induced hyperkalemia: Old culprits and new offenders. Am. J. Med. 109, 307–314.

11. Larsen, H.R. (2010) Importance of potassium. Online: http://afibbers.org/resources/potassium.pdf.

12. Terra, S.G. (2003) Angiotensin receptor blockers. Circulation. 107, e215-e216.

13. Sawyer, N., Gabriel, R. (1988) Progressive hypokalaemia in elderly patients taking three thiazide potassium-sparing diuretic combinations for thirty-six months. Postgrad. Med. J. 64, 434-437.

14. Ramsay, L.E., Hettiarachchi, J., Fraser, R., Morton, J.J. (1980) Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin. Pharmacol. Ther. 27, 533–543.

15. Jackson, P.R., Ramsay, L.E., Wakefield, V. (1982) Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. Br. J. Clin. Pharmacol.14, 257–263.

16. Stepan, V.M., Hammer, H.F., Krejs, G.J. (1997) Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics. Eur. J. Gastroenterol. Hepatol. 9, 1001-1004.

17. Herman, E., Rado, J. (1966) Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema. Arch. Neurol. 15, 74-77.

18. Herman, E., Rado, J. (1967) Hyperkalemia with fatal paralysis in a diabetic patient treated with aldactone. Orv. Hetil. 108, 74-76.

19. Good, C.B., McDermott, L., McCloskey, B. (1995) Diet and serum potassium in patients on ACE inhibitors. JAMA. 274, 538.

20. Rush, J.E., Merrill, D.D. (1987) The Safety and tolerability of lisinopril in clinical trials. J. Cardiovasc. Pharmacol. 9, S99–S107.

21. O’Keeffe, S., Grimes, H., Finn, J. i sur. (1992) Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure.Cardiology. 80, 100-105.

22. Burnakis, T.G., Mioduch, H.J. (1984) Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch. Intern. Med. 144, 2371–2372.

23. Ray, K., Dorman, S., Watson, R. (1999) Severe hyperkalemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.J. Hum. Hypertens. 13, 717–720.

24. Henry, C. (2002) Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J. Psychiat. Neurosci. 27, 104–107.

25. Kleiner J, Altshuler L, Hendrick V, Hershman JM. (1999) Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J. Clin. Psychiat. 60, 249-255.

26. Perrild, H., Hegedus, L., Baastrup, P.C., Kayser, L., Kastberg, S. (1990) Thyroid function and ultrasonically determined thyroid size in patients receiving long-term lithium treatment. Am. J. Psychiat. 147, 1518-1521.

27. Bocchetta, A., Bernardi, F., Pedditzi, M. i sur. (1991) Thyroid abnormalities during lithium treatment. Acta Psychiatr. Scand. 83, 193-198.

28. Lazarus JH. (2009) Lithium and thyroid. Best Pract. Res. Clin. Endocrinol. Metab. 23, 723-733.

29. Higdon, J., Drake, V. (2012) An Evidence-based Approach to Vitamins and Minerals: Health Benefits and Intake Recommendations, Thieme Publishing Group, Stuttgart.

30. Thomson, C.D., Campbell, J.M., Miller, J. i sur. (2009) Selenium and iodine supplementation: effect on thyroid function of older New Zealanders. Am. J. Clin. Nutr. 90, 1038-1046.

31. Levander, O.A., Whanger, P.D. (1996) Deliberations and evaluations of the approaches, endpoints and paradigms for selenium and iodine dietary recommendations. J. Nutr. 126, 2427S-2434S.

32. Zimmermann, M.B., Jooste, P.L., Pandav, C.S. (2008) Iodine-deficiency disorders. Lancet.372, 1251-1262.

33. Zimmermann, M.B., Jooste, P.L., Mabapa, N.S. i sur. (2007) Vitamin A supplementation in iodine-deficient African children decreases thyrotropin stimulation of the thyroid and reduces the goiter rate. Am. J. Clin. Nutr. 86, 1040-1044.

34. Zimmermann, M., Adou, P., Torresani, T. i sur. (2000) Persistence of goiter despite oral iodine supplementation in goitrous children with iron deficiency anemia in Côte d’Ivoire. Am. J. Clin. Nutr. 71, 88-93.